Dr. Daniel Christoph received his medical degree from the Ruhr-University of Bochum, Germany, in 2006. In his medical thesis at the Institute of Pharmacology of the University Hospital Essen he characterized the molecular mechanisms of the activation of the Ras-specific exchange factor RasGRP1 by the EGF receptor.
He started his specialization in Internal Medicine and Hematology/Oncology at the West German Cancer Center under the supervision of Professor Siegfried Seeber and Dr. Wilfried Eberhardt. From 2006 to 2009 he was involved in several Phase I and II clinical trials at this center.
Currently he is a grant recipient of the International Association on the Study of Lung Cancer (IASLC) and he is working at the University of Colorado Denver in Dr. Fred Hirsch’s Biomarker Analysis Laboratory for research in Thoracic Oncology. During this time he will continue work on his 3rd academic degree focusing on the analysis of resistance against pemetrexed in lung cancer as well in pleural mesothelioma.
Evaluation of predictive biomarkers for pemetrexed therapy using circulating tumor cells (CTCs) is also being performed. Depending on the experimental results, prospective clinical trials enrolling lung cancer and pleura mesothelioma patients should be conducted by him in 2013.